Drug Profile
Influenza virus vaccine quadrivalent - Seqirus
Alternative Names: Adjuvanted quadrivalent influenza vaccine - Seqirus; Adjuvanted quadrivalent influenza vaccine surface antigen inactivated - Seqirus; Adjuvanted quadrivalent subunit influenza virus vaccine - Seqirus; aIIV-B - Seqirus; aIIV-C - Seqirus; aQII; aQIV - Seqirus; aQIVc - Seqirus; Cell based quadrivalent subunit influenza virus vaccine - Seqirus; FLUAD QUADRIVALENT; Fluad Tetra; IIV-A - Seqirus; MF59 Adjuvanted Cell-derived Quadrivalent Influenza vaccine; MF59 adjuvanted quadrivalent subunit inactivated cell-derived influenza vaccine - Seqirus; MF59-Adjuvanted influenza vaccine - Seqirus; MF59-Adjuvanted quadrivalent subunit inactivated Influenza Vaccine - Seqirus; MF59® - Adjuvanted seasonal influenza vaccine - Seqirus; Subunit inactivated influenza vaccine - SeqirusLatest Information Update: 21 Nov 2023
Price :
$50
*
At a glance
- Originator Novartis
- Developer Novartis; Seqirus
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Influenza virus infections
Most Recent Events
- 03 Nov 2023 Phase-III clinical trials in Influenza virus infections (Prevention) in Denmark (IM) (NCT06015282)
- 29 Aug 2023 Seqirus plans a phase III (Celljuvant Study) trial in Influenza virus infections (Prevention) (IM) in October 2023 (NCT06015282)
- 31 Mar 2023 Seqirus completes a phase II trial for Influenza virus infections (Prevention, In adults, In the elderly) USA (IM) (NCT05501561)